Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab as a treatment for adult immune thrombocytopenia
2019-004683-22Phase 2Completed
- Sponsor
- Ostfold Hospital Trust
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in immune thrombocytopenia (ITP), sponsored by Ostfold Hospital Trust. Primary endpoint: Primary - safety run-in endpoints. Started Apr 2020; status: completed.
02
Drugs
daratumumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2019-004683-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004683-22.